ESC 2015: ‘Shocking’ Outcomes Of Sleep Apnea-Heart Failure Trial Spell Gloom For ResMed
This article was originally published in Clinica
Executive Summary
ResMed shareholders could very well see their stocks in the respiratory monitoring company take a thrashing, following the publication of the results of its SERVE-HF study which the co-principal investigator said “shocked both the respiratory and cardiology community”.